Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

47.52 -1.06 (-2.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,060,307
Open 48.85
Bid (Size) 46.60 (2)
Ask (Size) 47.52 (5)
Prev. Close 48.58
Today's Range 47.32 - 49.03
52wk Range 25.57 - 75.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Could Structure Therapeutics Become the Next Novo Nordisk?
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds. 
Via The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily

Performance

YTD
+17.65%
+17.65%
1 Month
+32.81%
+32.81%
3 Month
+36.55%
+36.55%
6 Month
+40.47%
+40.47%
1 Year
+49.20%
+49.20%

More News

Read More
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Via The Motley Fool
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
Via Investor's Business Daily
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Via The Motley Fool
Top Names Performance Update - Saturday, June 8
Via Talk Markets
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
From Structure Therapeutics Inc.
Via GlobeNewswire
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
Via InvestorPlace
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Via Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
From Structure Therapeutics Inc.
Via GlobeNewswire
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Via InvestorPlace
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.